Drug typically used for opioid addiction could be Long COVID treatment
Low-dose naltrexone (LDN) has been identified as a potential treatment for Long COVID after a ground-breaking Griffith University study found...
Low-dose naltrexone (LDN) has been identified as a potential treatment for Long COVID after a ground-breaking Griffith University study found...
Striking brain similarities have been detected in patients who experience Long COVID and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), in particular,...
Unlocking the secrets behind immune exhaustion in ME/CFS and Long COVID patients.
In a world-first discovery, Griffith University researchers have discovered faulty cell function in veterans suffering from Gulf War Illness (GWI),...
Researchers from Griffith University’s National Centre for Neuroimmunology and Emerging Diseases (NCNED) have made a groundbreaking discovery that could bring...
Researchers find overlap in long COVID and ME/CFS patients using MRI.
Researchers will track progression of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).
People with Long COVID in Australia have poor health outcomes that are comparable with another emerging disease known as myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).
Calls for new national clinical guidelines to improve the care of hundreds of thousands of Australians with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), and potentially thousands more with Long Covid.
Griffith University’s research into the potential overlap between Long COVID and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) has received a major boost thanks to a $6.4 million grant from the Stafford Fox Medical Research Foundation.